Bristol-Myers Squibb (NYSE:BMY) and Evotec have advanced molecular glue candidate BMS-986506 into Phase 1 trials for clear cell renal cell carcinoma. The program marks the first clinical-stage asset ...
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified ...
Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or ...
Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in ...
Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that the first patient ...
ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy –– ARV-102 ...
Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...
A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...
The end of the undruggable: Targeted protein degradation therapies open new frontiers in cancer care
Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...
Edited by: Thomas W. Durso and Karen Young Kreeger M. Hochstrasser, "Ubiquitin, proteasomes, and the regulation of intracellular protein degradation," Current Opinion in Cell Biology, 7:215-23, 1995. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results